Etentamig Clinical Trials (2026): 11 Studies for Multiple Myeloma & Relapsed/Refractory Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Etentamig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Multiple Myeloma & Relapsed/Refractory Multiple Myeloma) and 2,713 total planned enrollment. 1 Phase 3 Etentamig trial are listed. 7 Etentamig clinical trials are actively recruiting at 75 U.S. sites across 25 states. Most recent activity: NCT07095452 (Jan 2042).
Where to Participate: All Etentamig Trial Sites in the U.S. (75 sites across 25 states)
Every actively recruiting Etentamigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Mayo Clinic Arizona /ID# 251405 | Phoenix85054 | NCT05650632 | Map |
| AZ | Mayo Clinic Hospital Scottsdale /ID# 278349 | Scottsdale85259 | NCT07095452 | Map |
| AR | Highlands Oncology Group - Springdale /ID# 267742 | Springdale72762 | NCT05650632 | Map |
| CA | Beverly Hills Cancer Center /ID# 266921 | Beverly Hills90211 | NCT06896916 | Map |
| CA | City of Hope National Medical Center /ID# 273132 | Duarte91010 | NCT06892522 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911 | Irvine92618 | NCT06892522 | Map |
| CA | Cedars-Sinai Medical Center /ID# 278238 | Los Angeles90048 | NCT07095452 | Map |
| CO | Rocky Mountain Cancer Centers - Aurora /ID# 268574 | Aurora80012 | NCT05650632 | Map |
| CO | Colorado Blood Cancer Institute /ID# 273129 | Denver80218 | NCT06892522 | Map |
| CO | Colorado Blood Cancer Institute /ID# 273751 | Denver80218 | NCT06896916 | Map |
| CO | Colorado Blood Cancer Institute /ID# 279080 | Denver80218 | NCT07095452 | Map |
| DE | Medical Oncology Hematology Consultants /ID# 268560 | Newark19713 | NCT05650632 | Map |
| FL | Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856 | Miami33136 | NCT06158854 | Map |
| FL | Moffitt Cancer Center /ID# 272628 | Tampa33612 | NCT06892522 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 274830 | Atlanta30322 | NCT06892522 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 277667 | Atlanta30322 | NCT07095452 | Map |
| IL | Hope And Healing Cancer Services /ID# 268536 | Hinsdale60521 | NCT05650632 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 268179 | Fort Wayne46804 | NCT05650632 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 278141 | Fort Wayne46804 | NCT07095452 | Map |
| IN | Franciscan St. Francis Health /ID# 280928 | Indianapolis46237 | NCT05650632 | Map |
| LA | Tulane University School of Medicine /ID# 251204 | New Orleans70112 | NCT05650632 | Map |
| MA | Boston Medical Center /ID# 255066 | Boston02118 | NCT06158854 | Map |
| MN | Minnesota Oncology - Minneapolis Clinic /ID# 278720 | Minneapolis55404 | NCT07095452 | Map |
| MN | Mayo Clinic - Rochester /ID# 251164 | Rochester55905-0001 | NCT05650632 | Map |
| MN | Mayo Clinic - Rochester /ID# 255258 | Rochester55905-0001 | NCT06158854 | Map |
| MN | Mayo Clinic Hospital Rochester /ID# 277886 | Rochester55905 | NCT07095452 | Map |
| MO | Washington University /ID# 266972 | St Louis63110 | NCT06896916 | Map |
| NE | NHO Revive Research Institute, LLC /ID# 267869 | Lincoln68506 | NCT05650632 | Map |
| NE | Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497 | Omaha68130 | NCT05650632 | Map |
| NJ | Rutgers Cancer Institute of New Jersey /ID# 266833 | New Brunswick08901 | NCT06896916 | Map |
| NY | Columbia University Medical Center /ID# 255068 | New York10032-3729 | NCT06158854 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 255408 | New York10029 | NCT06158854 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 277844 | New York10029 | NCT07095452 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282 | New York10065 | NCT06896916 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946 | New York10065 | NCT07095452 | Map |
| NY | Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167 | New York10065-6007 | NCT05650632 | Map |
| NY | Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073 | New York10065-6007 | NCT06158854 | Map |
| NY | Mount Sinai - The Tisch Cancer Institute /ID# 272470 | New York10029 | NCT06892522 | Map |
| NY | Mt Sinai /ID# 251166 | New York10029-6542 | NCT05650632 | Map |
| NY | Weill Cornell Medical College /ID# 272517 | New York10065 | NCT06892522 | Map |
| NY | Weill Cornell Medicine Myeloma Center /ID# 278216 | New York10065 | NCT07095452 | Map |
| NC | University of North Carolina /ID# 251203 | Chapel Hill27514 | NCT05650632 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 274667 | Chapel Hill27514 | NCT06892522 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 277708 | Chapel Hill27514 | NCT07095452 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 255074 | Charlotte28204 | NCT06158854 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 276193 | Charlotte28204-2990 | NCT06892522 | Map |
| NC | University Of North Carolina Health Care - Hillsborough Campus /ID# 278230 | Hillsborough27278 | NCT06896916 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 251165 | Winston-Salem27157 | NCT05650632 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 255851 | Winston-Salem27157 | NCT06158854 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 274847 | Winston-Salem27157 | NCT06892522 | Map |
| OH | Oncology Hematology Care - Blue Ash /ID# 272918 | Cincinnati45252 | NCT06892522 | Map |
| OH | University Of Cincinnati Medical Center /ID# 251746 | Cincinnati45219 | NCT05650632 | Map |
| OH | The Ohio State University /ID# 271336 | Columbus43210 | NCT06892522 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 267088 | Eugene97401 | NCT05650632 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 278721 | Eugene97401 | NCT07095452 | Map |
| OR | Oregon Medical Research Center /ID# 255119 | Portland97239 | NCT06158854 | Map |
| TN | SCRI Oncology Partners /ID# 278353 | Nashville37203 | NCT07095452 | Map |
| TN | Vanderbilt Ingram Cancer Center /ID# 252470 | Nashville37232-0021 | NCT05650632 | Map |
| TN | Vanderbilt University Medical Center. /ID# 273510 | Nashville37232 | NCT06158854 | Map |
| TX | Texas Oncology - Central/South Texas /ID# 268563 | Austin78705 | NCT05650632 | Map |
| TX | Texas Oncology - Dallas - Worth Street /ID# 280064 | Dallas75246 | NCT05650632 | Map |
| TX | University of Texas - Southwestern Medical Center /ID# 274360 | Dallas75235 | NCT06892522 | Map |
| TX | Oncology Consultants /ID# 268323 | Houston77030 | NCT05650632 | Map |
| TX | Texas Oncology - The Woodlands /ID# 278726 | The Woodlands77380 | NCT07095452 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 268877 | Tyler75702 | NCT05650632 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 278725 | Tyler75702 | NCT07095452 | Map |
| UT | Huntsman Cancer Institute /ID# 272575 | Salt Lake City84112 | NCT06892522 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 268559 | Fairfax22031 | NCT05650632 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 278716 | Fairfax22031 | NCT07095452 | Map |
| VA | Blue Ridge Cancer Care - Roanoke /ID# 278722 | Roanoke24014 | NCT07095452 | Map |
| WA | Fred Hutchinson Cancer Center. /ID# 267940 | Seattle98109-4405 | NCT05650632 | Map |
| WA | Swedish Medical Center - Seattle /ID# 268052 | Seattle98104 | NCT06896916 | Map |
| WA | University of Washington /ID# 261581 | Seattle98109 | NCT06158854 | Map |
| WA | Northwest Medical Specialties Tacoma /ID# 267117 | Tacoma98405 | NCT05650632 | Map |
| WI | Wisconsin Medical Center /ID# 255836 | Milwaukee53226 | NCT06158854 | Map |
Etentamig clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 2 | 3 | 5 | |
| P1/P2 | 2 | 2 | 4 | |
| P2/P3 | 1 | 1 | ||
| P3 | 1 | 1 |
Recruiting Etentamig clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | P2/P3 | Multiple Myeloma | 660 | Jan 2026 |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | P1/P2 | Recurrent Waldenstrom Macroglobulinemia | 38 | Oct 2026 |
| NCT07600151 | CONQUISTADOREtenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | P1/P2 | Myeloma Multiple | 220 | Dec 2026 |
| NCT06896916 | IVStudy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | Multiple Myeloma | 135 | Aug 2025 |
| NCT06892522 | AEA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations | P1/P2 | Multiple Myeloma | 602 | Jun 2025 |
| NCT06158854 | AEA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion | P1/P2 | Immunoglobulin Light Chain (AL) Amyloidosis | 76 | Apr 2024 |
| NCT05650632 | IVA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | Multiple Myeloma | 210 | Mar 2023 |
Etentamig clinical trials by indication
Multiple Myeloma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07095452 | — | P2/P3 | recruiting | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant |
| NCT06896916 | IV | P1 | recruiting | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06892522 | AE | P1/P2 | recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations |
| NCT05650632 | IV | P1 | recruiting | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06223516 | SC | P1 | active not recruiting | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06158841 | CERVINO | P3 | active not recruiting | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma |
Relapsed/Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05259839 | IV | P1 | active not recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma |
| NCT05286229 | IV | P1 | active not recruiting | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan |
Myeloma Multiple (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07600151 | CONQUISTADOR | P1/P2 | not yet recruiting | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma |
Recurrent Waldenstrom Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07420959 | — | P1/P2 | not yet recruiting | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia |
Immunoglobulin Light Chain (AL) Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06158854 | AE | P1/P2 | recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion |
Etentamig pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CERVINO | NCT06158841 | P3 | active not recruiting | Multiple Myeloma | 421 | — |
All Etentamig trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | P2/P3 | recruiting | 660 | AbbVie | Jan 2026 | |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | P1/P2 | not yet recruiting | 38 | Mayo Clinic | Oct 2026 | |
| NCT07600151 | CONQUISTADOR | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | P1/P2 | not yet recruiting | 220 | Universitätsklinikum Hamburg-Eppendorf | Dec 2026 |
| NCT06896916 | IV | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 135 | AbbVie | Aug 2025 |
| NCT06892522 | AE | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations | P1/P2 | recruiting | 602 | AbbVie | Jun 2025 |
| NCT05259839 | IV | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | P1 | active not recruiting | 283 | AbbVie | Oct 2022 |
| NCT06158854 | AE | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion | P1/P2 | recruiting | 76 | AbbVie | Apr 2024 |
| NCT05650632 | IV | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 210 | AbbVie | Mar 2023 |
| NCT06223516 | SC | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 60 | AbbVie | Jun 2024 |
| NCT06158841 | CERVINO | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | P3 | active not recruiting | 421 | AbbVie | May 2024 |
| NCT05286229 | IV | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | P1 | active not recruiting | 8 | AbbVie | Mar 2022 |
Etentamig clinical trials: frequently asked questions
- How many Etentamig clinical trials are there?
- 11 Etentamig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants.
- Are Etentamig clinical trials recruiting in 2026?
- Yes — 5 Etentamig trials are actively recruiting in 2026, with 75 U.S. sites across 25 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Etentamig being studied for?
- Etentamig is being studied for Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Immunoglobulin Light Chain (AL) Amyloidosis, Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia and 2 more. The trials are grouped by indication on this page.
- What phase is Etentamig in?
- Etentamig clinical trials span 1 Phase 3, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Etentamig clinical trials?
- The lead sponsor across the most Etentamig trials is AbbVie, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Etentamigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: